
Tucatinib/Trastuzumab Yields Durable Responses in HER2-Mutated Metastatic Breast Cancer
Findings from the final analysis of the phase 2 SGNTUC-019 trial (NCT04579380) demonstrated durable antitumor activity and a high disease control rate (DCR) with the combination of tucatinib (Tukysa) and trastuzumab (Herceptin) in patients with HER2- …